In a single month, three reports describe different views of China's economic future
The director known for adding depth to the mundane will make the case that Gap's "Dress Normal" doesn't equal "dress boring"
Three times more money has been spent on the race for the state's school's chief than on the governor's race
An IT expert offers an estimate of what a 50-employee small business might spend to protect against cyberattacks
A slowdown in funding could end the growth of U.S. oil production
Independent developer Lucas Menge took it upon himself to adapt the smartwatch's home screen for the iPhone
Starbucks will start a coffee delivery program in late 2015, giving other companies' employees one fewer excuse to leave the office
New government rules could block 500 colleges from federal aid money and put hundreds more in danger of losing it
Candy sales are increasing, but big drugstores and supermarkets benefit more than local candy shops
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."